Advertisement
Advertisement
TECH
Bio-Techne Corp.
53.83
USDSponsored
+0.03
+0.06%
Apr 07, 15:59 UTC -4
Closed
After-Market
53.47
-0.36
-0.67%
TECH Earnings Reports
Positive Surprise Ratio
TECH beat 25 of 40 last estimates.
63%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$323.43M
/$0.54
Implied change from Q2 26 (Revenue/ EPS)
+9.31%
/+17.39%
Implied change from Q3 25 (Revenue/ EPS)
+2.29%
/-3.57%
Bio-Techne Corp. earnings per share and revenue
On Feb 04, 2026, TECH reported earnings of 0.46 USD per share (EPS) for Q2 26, beating the estimate of 0.44 USD, resulting in a 3.95% surprise. Revenue reached 295.88 million, compared to an expected 295.99 million, with a -0.04% difference. The market reacted with a +6.25% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 16 analysts forecast an EPS of 0.54 USD, with revenue projected to reach 323.43 million USD, implying an increase of 17.39% EPS, and increase of 9.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Bio-Techne Corp.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bio-Techne Corp. reported EPS of $0.46, beating estimates by 3.95%, and revenue of $295.88M, -0.04% below expectations.
How did the market react to Bio-Techne Corp.'s Q2 2026 earnings?
The stock price moved up 6.25%, changed from $64.63 before the earnings release to $68.67 the day after.
When is Bio-Techne Corp. expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Bio-Techne Corp.'s next earnings report?
Based on 16
analysts, Bio-Techne Corp. is expected to report EPS of $0.54 and revenue of $323.43M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement